Clarivate Reports First Quarter 2026 Results
Rhea-AI Summary
Clarivate (NYSE: CLVT) reported Q1 2026 results with revenues of $585.5M and Adjusted EBITDA of $241.2M. Adjusted net income rose to $119.3M and adjusted EPS to $0.18. The company generated $78.9M free cash flow and used cash to retire $143.1M of debt. Clarivate reaffirmed full‑year 2026 guidance, including $2.30B–$2.42B revenues, $980M–$1.04B Adjusted EBITDA, and $365M–$435M free cash flow.
Positive
- Adjusted net income +24.5% to $119.3M
- Retired $143.1M of debt, strengthening the balance sheet
- Reaffirmed full‑year guidance: $980M–$1.04B Adjusted EBITDA and $365M–$435M FCF
Negative
- Free cash flow down 28.5% to $78.9M versus prior year quarter
- Net cash from operations declined 21.3% to $134.7M
Key Figures
Market Reality Check
Peers on Argus
CLVT is up 2.03% while peers show mixed moves: modest gains in CNXC and WNS but declines in DXC, GLOB, and VNET, indicating a stock-specific reaction rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Q4 & FY25 earnings | Positive | +39.9% | Full-year 2025 results with stronger cash flow, higher ACV, and 2026 guidance. |
| Oct 29 | Q3 2025 earnings | Positive | -4.1% | Q3 2025 showed stable revenue and better cash returns but EBITDA declined. |
| Jul 30 | Q2 2025 earnings | Positive | -4.3% | Q2 2025 revenue dipped on divestitures but organic growth and cash flow improved. |
| Apr 29 | Q1 2025 earnings | Neutral | +17.3% | Mixed Q1 2025 with slight organic growth and reaffirmed 2025 outlook. |
| Feb 19 | Q4 & FY24 earnings | Negative | -1.4% | FY24 revenue and organic trends declined amid strategic review and product cuts. |
Earnings releases often trigger sizable moves, with both strong rallies on upbeat guidance and selloffs when results are mixed despite improving fundamentals.
Over the past year, Clarivate’s earnings updates have focused on shifting toward a subscription-heavy, recurring revenue model, improving cash generation, and reducing debt. Prior quarters highlighted stable or modest organic growth, narrowing net losses, and reaffirmed or raised guidance, with some periods of share repurchases and accelerated debt repayment. Market reactions were mixed: some reports with guidance strength and cash improvements saw double-digit gains, while others with softer revenue trends or margin pressure prompted declines. Today’s Q1 2026 results continue the themes of organic growth, margin expansion, and deleveraging while reaffirming the 2026 outlook.
Historical Comparison
In the past five earnings announcements, CLVT moved an average of 9.46% over the following day, with both large rallies and notable drops, highlighting that earnings have been a key volatility catalyst.
Earnings releases show a progression toward higher recurring revenue, modest organic ACV growth, stronger free cash flow, and active balance-sheet management, with guidance for 2026 building on these trends.
Regulatory & Risk Context
An effective Form S-3ASR shelf filed on 2025-11-04 allows Clarivate to offer ordinary shares, preferred shares, debt securities, warrants, purchase contracts, and units, and also registers the resale of up to 245,076,317 ordinary shares by existing holders. Clarivate will not receive proceeds from selling shareholder resales, while any primary issuance would be for general corporate purposes.
Market Pulse Summary
This announcement details Q1 2026 results showing modest organic revenue growth, improved net loss, and higher adjusted EBITDA, alongside lower free cash flow and slightly lower total revenue versus last year. Management reaffirmed 2026 guidance, including revenues of $2.30B–$2.42B and free cash flow of $365M–$435M, and highlighted continued deleveraging. Historically, earnings have been key catalysts for Clarivate, so investors may watch recurring organic growth, cash generation, and debt reduction against these targets in subsequent quarters.
Key Terms
free cash flow financial
adjusted ebitda financial
adjusted net income financial
adjusted diluted eps financial
organic acv financial
non-gaap financial
gaap financial
AI-generated analysis. Not financial advice.
— Value Creation Plan delivering accelerated organic revenue growth —
— Utilized solid free cash flow generation to deleverage —
— Reaffirms 2026 financial outlook —
Executive Commentary
Matti Shem Tov, Chief Executive Officer:
"We are off to a solid start to 2026, with first‑quarter results demonstrating tangible progress against the Value Creation Plan we launched in early 2025. Execution of the VCP is strengthening the quality and durability of our performance. We are simplifying and optimizing our business model, improving commercial effectiveness, and accelerating innovation across the portfolio. Together, these actions are expanding margins, increasing free cash flow generation, and improving the consistency of our results. AI is becoming a meaningful enabler of this progress, embedded in our products to enhance customer workflows and decision‑making, and deployed internally to drive efficiency and scalability. With a more focused strategy and continued execution discipline, we remain confident in our ability to deliver sustainable growth and long‑term value for shareholders."
Jonathan Collins, Executive Vice President and Chief Financial Officer:
"We generated solid free cash flow of
First Quarter 2026 Results
Total revenues for the first quarter 2026 were
Organic ACV increased
Net loss for the first quarter 2026 improved to
Clarivate generated
Selected Financial Information
(In millions, except percentages and per share data), (unaudited) | Three Months Ended March 31, | Change | |||||
2026 | 2025 | $ | % | ||||
Revenues | $ 585.5 | $ 593.7 | $ (8.2) | (1.4) % | |||
Net income (loss) | $ (40.2) | $ (103.9) | $ 63.7 | 61.3 % | |||
Adjusted net income(1) | $ 119.3 | $ 95.8 | $ 23.5 | 24.5 % | |||
Adjusted EBITDA(1) | $ 241.2 | $ 233.2 | $ 8.0 | 3.4 % | |||
Diluted EPS | $ (0.06) | $ (0.15) | $ 0.09 | 60.0 % | |||
Adjusted diluted EPS(1) | $ 0.18 | $ 0.14 | $ 0.04 | 28.6 % | |||
Net cash provided by operating activities | $ 134.7 | $ 171.2 | $ (36.5) | (21.3) % | |||
Free cash flow(1) | $ 78.9 | $ 110.3 | $ (31.4) | (28.5) % | |||
First Quarter 2026 Commentary
Subscription revenues were
Re-occurring revenues were
Total recurring revenues, consisting of subscription and re-occurring revenues, increased
Transactional revenues were
Balance Sheet and Cash Flow
As of March 31, 2026, cash and cash equivalents were
Total debt outstanding was
Net cash provided by operating activities for the three months ended March 31, 2026 was
Reaffirms outlook for 2026 (forward-looking statement)
The full-year outlook presented below assumes no further acquisitions, divestitures, or other unanticipated events.
Full Year 2026 Outlook | |
Organic ACV | |
Recurring Organic Revenue Growth | |
Revenues | |
Adjusted EBITDA(1) | |
Adjusted EBITDA Margin(1) | |
Adjusted Diluted EPS(1)(2) | |
Free Cash Flow(1) |
Notes to press release | |
(1) | Non-GAAP measure. Please see "Reconciliations to Certain Non-GAAP Measures" in this release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this press release. |
(2) | Adjusted diluted EPS for 2026 is calculated based on approximately 650 million fully diluted adjusted weighted average ordinary shares outstanding. |
Conference Call and Webcast
Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:30 a.m. Eastern Time. The webcast is open to all interested parties and may include forward-looking information.
The live webcast of the earnings call will be accessible through the investor relations section of the Company's website. To join the webcast please visit https://events.q4inc.com/attendee/839803049.
Interested parties may access the live audio broadcast.
A replay of the webcast will also be available on https://ir.clarivate.com beginning two hours after the conclusion of the live call and will remain available for one year.
Use of Non-GAAP Financial Measures
This release contains financial measures that have not been prepared in accordance with
We use non-GAAP measures internally in our operational and financial decision-making, to assess the operating performance of our business, to assess performance for employee compensation purposes, and to decide how to allocate resources. We believe that such measures allow us to focus on what we deem to be more reliable indicators of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. Further, these measures can be useful in evaluating our performance against our peer companies because we believe they provide users with valuable insight into key components of our GAAP financial disclosure. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.
Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all.
Forward-Looking Statements
This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements" within the meaning of the "safe harbor provisions" of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all matters that are not historical facts, including statements relating to our intentions, beliefs, or current expectations concerning, among other things, the anticipated divestiture of our LS&H business or any other strategic transactions we may explore, anticipated cost savings, results of operations, financial condition, liquidity, capital allocation plans and share repurchases, foreign exchange impacts, prospects, growth, strategies, and the markets in which we operate, our financial guidance for the fiscal year 2026 and key drivers thereof and underlying assumptions, the impact or anticipated benefits of our Value Creation Plan and other growth strategies, the global macroeconomic uncertainty and volatility, the impact of artificial intelligence ("AI") on our business and strategy, and the timing of any of the foregoing. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "seeks," "projects," "intends," "plans," "may," "will," or "should" or, in each case, their negative or other variations or comparable terminology. Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property, and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Condensed Consolidated Balance Sheets (Unaudited)
| |||
(In millions) | March 31, 2026 | December 31, 2025 | |
ASSETS | |||
Current assets: | |||
Cash and cash equivalents, including restricted cash | $ 242.2 | $ 329.2 | |
Accounts receivable, net | 882.9 | 821.7 | |
Prepaid expenses | 109.1 | 94.2 | |
Other current assets | 66.9 | 64.9 | |
Total current assets | 1,301.1 | 1,310.0 | |
Property and equipment, net | 50.9 | 52.7 | |
Other intangible assets, net | 7,863.7 | 8,008.1 | |
Goodwill | 1,566.6 | 1,566.7 | |
Other non-current assets | 85.8 | 68.1 | |
Deferred income taxes | 16.5 | 17.2 | |
Operating lease right-of-use assets | 42.5 | 46.6 | |
Total assets | $ 10,927.1 | $ 11,069.4 | |
LIABILITIES AND SHAREHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable | $ 135.7 | $ 150.6 | |
Accrued compensation | 100.6 | 146.7 | |
Accrued expenses and other current liabilities | 286.3 | 273.0 | |
Current portion of deferred revenues | 1,000.4 | 878.6 | |
Current portion of operating lease liability | 17.6 | 18.4 | |
Current portion of long-term debt | 1.5 | 101.5 | |
Total current liabilities | 1,542.1 | 1,568.8 | |
Long-term debt | 4,281.6 | 4,321.5 | |
Other non-current liabilities | 75.9 | 86.2 | |
Deferred income taxes | 205.0 | 212.1 | |
Operating lease liabilities | 33.7 | 37.9 | |
Total liabilities | 6,138.3 | 6,226.5 | |
Commitments and contingencies | |||
Shareholders' equity: | |||
Ordinary Shares, no par value; unlimited shares authorized; 639.2 and 640.7 shares issued | 12,801.3 | 12,810.6 | |
Accumulated other comprehensive loss | (457.7) | (453.1) | |
Accumulated deficit | (7,554.8) | (7,514.6) | |
Total shareholders' equity | 4,788.8 | 4,842.9 | |
Total liabilities and shareholders' equity | $ 10,927.1 | $ 11,069.4 | |
Condensed Consolidated Statements of Operations (Unaudited)
| |||
Three Months Ended March 31, | |||
(In millions, except per share data) | 2026 | 2025 | |
Revenues | $ 585.5 | $ 593.7 | |
Operating expenses: | |||
Cost of revenues | 192.1 | 207.0 | |
Selling, general and administrative costs | 176.3 | 178.4 | |
Depreciation and amortization | 184.0 | 185.4 | |
Restructuring costs | 12.0 | 24.7 | |
Other operating expense (income), net | (9.1) | 19.0 | |
Total operating expenses | 555.3 | 614.5 | |
Income (loss) from operations | 30.2 | (20.8) | |
Interest expense, net | 59.0 | 64.3 | |
Income (loss) before income taxes | (28.8) | (85.1) | |
Provision (benefit) for income taxes | 11.4 | 18.8 | |
Net income (loss) | $ (40.2) | $ (103.9) | |
Per share: | |||
Basic | $ (0.06) | $ (0.15) | |
Diluted | $ (0.06) | $ (0.15) | |
Weighted average shares used to compute earnings per share: | |||
Basic | 640.7 | 689.8 | |
Diluted | 640.7 | 689.8 | |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| |||
Three Months Ended March 31, | |||
(In millions) | 2026 | 2025 | |
Cash Flows From Operating Activities | |||
Net income (loss) | $ (40.2) | $ (103.9) | |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
Depreciation and amortization | 184.0 | 185.4 | |
Share-based compensation | 14.2 | 10.7 | |
Amortization and write-off of debt issuance costs | 3.3 | 2.9 | |
Other operating activities | (16.8) | 21.6 | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (62.3) | (33.6) | |
Prepaid expenses | (15.2) | (14.7) | |
Other assets | (8.7) | 1.9 | |
Accounts payable | (14.5) | (5.8) | |
Accrued expenses and other current liabilities | (34.8) | (3.9) | |
Deferred revenues | 129.3 | 111.3 | |
Operating leases, net | (0.8) | (1.5) | |
Other liabilities | (2.8) | 0.8 | |
Net cash provided by operating activities | 134.7 | 171.2 | |
Cash Flows From Investing Activities | |||
Capital expenditures | (55.8) | (60.9) | |
Net cash used for investing activities | (55.8) | (60.9) | |
Cash Flows From Financing Activities | |||
Principal payments on debt | (138.5) | – | |
Repurchases of ordinary shares | (18.1) | (50.0) | |
Payments related to tax withholding for share-based compensation | (5.3) | (6.4) | |
Other financing activities | (0.4) | (0.2) | |
Net cash used for financing activities | (162.3) | (56.6) | |
Effects of exchange rates | (3.6) | 5.1 | |
Net change in cash and cash equivalents, including restricted cash | (87.0) | 58.8 | |
Cash and cash equivalents, including restricted cash, beginning of period | 329.2 | 295.2 | |
Cash and cash equivalents, including restricted cash, end of period | $ 242.2 | $ 354.0 | |
Supplemental Revenues Information
Annualized contract value ("ACV"), at any point in time, represents the annualized value of all active customer subscription-based license agreements for the next 12 months, assuming those coming up for renewal during the measurement period are renewed at their current price level. Our organic ACV grew
The following tables present our revenues by type and by segment for the periods indicated, as well as the components driving the changes between periods.
(In millions, except percentages); (unaudited) | Three Months Ended March 31, | Change | % of Change | ||||||||
2026 | 2025 | $ | % | Acquisitions | Disposals | FX | Organic | ||||
Subscription | $ 397.5 | $ 388.6 | $ 8.9 | 2.3 % | – % | (1.3) % | 1.9 % | 1.7 % | |||
Re-occurring | 108.6 | 105.9 | 2.7 | 2.5 % | – % | (0.1) % | 4.2 % | (1.6) % | |||
Recurring revenues | 506.1 | 494.5 | 11.6 | 2.3 % | – % | (1.1) % | 2.4 % | 1.0 % | |||
Transactional | 79.4 | 99.2 | (19.8) | (20.0) % | – % | (19.3) % | 1.3 % | (2.0) % | |||
Revenues | $ 585.5 | $ 593.7 | $ (8.2) | (1.4) % | – % | (4.2) % | 2.2 % | 0.6 % | |||
(In millions, except percentages); (unaudited) | Three Months Ended March 31, | Change | % of Change | ||||||||
2026 | 2025 | $ | % | Acquisitions | Disposals | FX | Organic | ||||
Academia & Government | $ 295.0 | $ 302.7 | $ (7.7) | (2.5) % | – % | (6.2) % | 1.7 % | 2.0 % | |||
Intellectual Property | 197.2 | 192.7 | 4.5 | 2.3 % | – % | – % | 3.6 % | (1.3) % | |||
Life Sciences & Healthcare | 93.3 | 98.3 | (5.0) | (5.1) % | – % | (6.9) % | 1.0 % | 0.8 % | |||
Revenues | $ 585.5 | $ 593.7 | $ (8.2) | (1.4) % | – % | (4.2) % | 2.2 % | 0.6 % | |||
Reconciliations to Certain Non-GAAP Measures
Adjusted EBITDA and Adjusted EBITDA margin
Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating performance. Net income (loss) margin is calculated by dividing Net income (loss) by Revenues. Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Revenues.
The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the three months ended March 31, 2026 and 2025 and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss) margin for the same periods:
Three Months Ended March 31, | |||
(In millions, except percentages); (unaudited) | 2026 | 2025 | |
Net income (loss) | $ (40.2) | $ (103.9) | |
Provision (benefit) for income taxes | 11.4 | 18.8 | |
Depreciation and amortization | 184.0 | 185.4 | |
Interest expense, net | 59.0 | 64.3 | |
Share-based compensation expense | 14.6 | 11.1 | |
Restructuring costs | 12.0 | 24.7 | |
Transaction related costs | 8.2 | 6.3 | |
Other(1) | (7.8) | 26.5 | |
Adjusted EBITDA | $ 241.2 | $ 233.2 | |
Net income (loss) margin | (6.9) % | (17.5) % | |
Adjusted EBITDA margin | 41.2 % | 39.3 % | |
(1) | Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. |
Adjusted net income and Adjusted diluted EPS
Adjusted net income represents Net income (loss), adjusted to exclude amortization related to acquired intangible assets, share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in net income (loss) for the period that we do not consider indicative of our ongoing operating performance and the associated income tax impact of such adjustments.
Adjusted diluted EPS is calculated by dividing Adjusted net income by Adjusted diluted weighted average shares. The Adjusted diluted weighted average shares calculation assumes that all instruments in the calculation are dilutive.
The following table presents our calculation of Adjusted net income and Adjusted diluted EPS for the three months ended March 31, 2026 and 2025 and reconciles these non-GAAP measures to our Net income (loss) and diluted EPS for the same periods:
Three Months Ended March 31, | |||||||
2026 | 2025 | ||||||
(In millions, except per share amounts); (unaudited) | Amount | Per Share | Amount | Per Share | |||
Net income (loss) and Diluted EPS | $ (40.2) | $ (0.06) | $ (103.9) | $ (0.15) | |||
Amortization related to acquired intangible assets | 135.4 | 0.21 | 136.3 | 0.20 | |||
Share-based compensation expense | 14.6 | 0.02 | 11.1 | 0.02 | |||
Restructuring costs | 12.0 | 0.02 | 24.7 | 0.04 | |||
Transaction related costs | 8.2 | 0.01 | 6.3 | 0.01 | |||
Other(1) | (6.2) | (0.01) | 26.5 | 0.03 | |||
Income tax impact of related adjustments | (4.5) | (0.01) | (5.2) | (0.01) | |||
Adjusted net income and Adjusted diluted EPS | $ 119.3 | $ 0.18 | $ 95.8 | $ 0.14 | |||
Adjusted weighted average ordinary shares, diluted | 647.3 | 695.2 | |||||
(1) | Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing operating performance. |
Free cash flow
Free cash flow represents Net cash provided by operating activities less Capital expenditures. The following table presents our calculation of Free cash flow for the three months ended March 31, 2026 and 2025 and reconciles this non-GAAP measure to Net cash provided by operating activities for the same periods:
Three Months Ended March 31, | |||
(In millions); (unaudited) | 2026 | 2025 | |
Net cash provided by operating activities | $ 134.7 | $ 171.2 | |
Capital expenditures | (55.8) | (60.9) | |
Free cash flow | $ 78.9 | $ 110.3 | |
Reconciliations to Certain Non-GAAP Measures - 2026 Outlook
Adjusted EBITDA and Adjusted EBITDA margin
The following table presents our calculation of Adjusted EBITDA and Adjusted EBITDA margin for the 2026 outlook and reconciles these non-GAAP measures to our Net income (loss) and Net income (loss) margin for the same period:
Year Ending December 31, 2026 (Forecasted) | |||
(In millions); (unaudited) | Low | High | |
Net income (loss) | $ (189) | $ (124) | |
Provision (benefit) for income taxes | 43 | 48 | |
Depreciation and amortization | 786 | 786 | |
Interest expense, net | 238 | 228 | |
Share-based compensation expense | 70 | 70 | |
Restructuring costs(1) | 25 | 25 | |
Transaction related costs | 13 | 13 | |
Other | (6) | (6) | |
Adjusted EBITDA | $ 980 | $ 1,040 | |
Net income (loss) margin | (8.2) % | (5.1) % | |
Adjusted EBITDA margin | 42.0 % | 43.5 % | |
(1) | Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan. |
Adjusted diluted EPS
The following table presents our calculation of Adjusted diluted EPS for the 2026 outlook and reconciles this non-GAAP measure to our Net income (loss) per share for the same period:
Year Ending December 31, 2026 (Forecasted) | |||
(Unaudited) | Low | High | |
Net income (loss) | $ (0.29) | $ (0.19) | |
Amortization related to acquired intangible assets | 0.84 | 0.84 | |
Share-based compensation expense | 0.11 | 0.11 | |
Restructuring costs(1) | 0.04 | 0.04 | |
Transaction related costs | 0.02 | 0.02 | |
Other | 0.01 | 0.01 | |
Income tax impact of related adjustments | (0.03) | (0.03) | |
Adjusted diluted EPS | $ 0.70 | $ 0.80 | |
Adjusted weighted average ordinary shares, diluted | ~650 million | ||
(1) | Reflects restructuring costs expected to be incurred in 2026 associated with the Value Creation Plan. |
Free cash flow
The following table presents our calculation of Free cash flow for the 2026 outlook and reconciles this non-GAAP measure to our Net cash provided by operating activities for the same period:
Year Ending December 31, 2026 (Forecasted) | |||
(In millions); (unaudited) | Low | High | |
Net cash provided by operating activities | $ 615 | $ 685 | |
Capital expenditures | (250) | (250) | |
Free cash flow | $ 365 | $ 435 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-reports-first-quarter-2026-results-302756497.html
SOURCE Clarivate Plc
FAQ
What were Clarivate's Q1 2026 revenue and adjusted EBITDA (CLVT)?
Q1 2026 revenue was $585.5M and Adjusted EBITDA was $241.2M. According to the company, revenue reflects disposals while organic trends improved slightly; Adjusted EBITDA rose year‑over‑year to $241.2M.
How much free cash flow did Clarivate (CLVT) generate in Q1 2026 and what is full‑year FCF guidance?
Q1 free cash flow was $78.9M; full‑year guidance is $365M–$435M. According to the company, Q1 FCF was used partly to repay debt and full‑year guidance assumes no further major transactions.
What debt actions did Clarivate (CLVT) take in Q1 2026 and how did it affect total debt?
Clarivate retired $143.1M of debt in Q1, reducing total debt to $4,326.8M. According to the company, repayments included accelerated redemption and repurchases at discounts to par.
Did Clarivate report organic growth in Q1 2026 and what were the subscription trends (CLVT)?
Organic ACV rose 1.6% and organic subscription revenue increased 1.7% in Q1. According to the company, subscription growth was driven by new customer wins and pricing, offsetting weaker transactional activity.
Will Clarivate (CLVT) hold an earnings webcast for Q1 2026 and how can investors access it?
Yes. The company held a Q1 2026 webcast and call at 9:30 a.m. ET on April 29, 2026. According to the company, the live webcast and replay are available via its investor relations website for one year.